Top

Published in:

Open Access 01-12-2020 | Multiple Myeloma | Original Article

Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen

Authors: Aneta Szudy-Szczyrek, Radosław Mlak, Michał Mielnik, Michał Szczyrek, Aleksandra Nowaczyńska, Iwona Homa-Mlak, Szymon Zmorzyński, Kinga Kuśmierczuk, Jacek Sompor, Agata Filip, Teresa Małecka-Massalska, Marek Hus

Published in: Annals of Hematology | Issue 12/2020

Abstract

Neutrophils to lymphocytes ratio (NLR) and platelets to lymphocytes ratio (PLR) are considered as laboratory markers of inflammation. They can be potentially useful in predicting the course of multiple neoplasms including selected hematological cancers. The aim of the study was to assess the value of NLR and PLR in predicting the effects of therapy and prognosis in multiple myeloma patients treated with thalidomide-based regimen. The study group consisted of 100 patients treated with the first line CTD (cyclophosphamide, thalidomide, and dexamethasone) chemotherapy. The NLR and PLR were calculated before treatment. High NLR was observed in patients with higher stage of the disease, with poor performance status, hypercalcemia, and high CRP. High PLR was associated with low BMI and high CRP. In patients with high NLR, significantly shorter PFS was observed (17 vs. 26 months, p = 0.0405). In addition, high values of NLR and PLR were associated with significantly shorter OS (38 vs. 79 months, p = 0.0010; 40 vs. 78 months, p = 0.0058). Summarizing, NLR and PLR have a significant independent prognostic value for multiple myeloma patients. Furthermore, the NLR can be a predictive marker for the outcome of thalidomide-based chemotherapy.

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BGM, Miguel JFS (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538–e548. https://doi.org/10.1016/S1470-2045(14)70442-5CrossRefPubMed

Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 28(5):1122–1128. https://doi.org/10.1038/leu.2013.313CrossRefPubMed

Greipp PR, San Miguel J, Durie BGM et al (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412–3420. https://doi.org/10.1200/JCO.2005.04.242CrossRefPubMed

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BGM, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P (2015) Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 33(26):2863–2869. https://doi.org/10.1200/JCO.2015.61.2267CrossRefPubMedPubMedCentral

Podar K, Chauhan D, Anderson KC (2009) Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 23(1):10–24. https://doi.org/10.1038/leu.2008.259CrossRefPubMed

Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell. 140(6):883–899. https://doi.org/10.1016/j.cell.2010.01.025CrossRefPubMedPubMedCentral

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell. 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013CrossRefPubMed

Shalapour S, Karin M (2015) Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 125(9):3347–3355. https://doi.org/10.1172/JCI80007CrossRefPubMedPubMedCentral

Wang D, DuBois RN (2015) Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis. 36(10):1085–1093. https://doi.org/10.1093/carcin/bgv123CrossRefPubMedPubMedCentral

10.

de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6(1):24–37. https://doi.org/10.1038/nrc1782CrossRefPubMed

11.

Shau HY, Kim A (1988) Suppression of lymphokine-activated killer induction by neutrophils. J Immunol 141(12):4395–4402PubMed

12.

Coussens LM, Tinkle CL, Hanahan D, Werb Z (2000) MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis. Cell. 103(3):481–490. https://doi.org/10.1016/S0092-8674(00)00139-2CrossRefPubMedPubMedCentral

13.

Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey J-N (2009) Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 16(3):614–622. https://doi.org/10.1245/s10434-008-0267-6CrossRefPubMed

14.

el Aziz LMA (2014) Blood neutrophil–lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4. Med Oncol 31(12):311. https://doi.org/10.1007/s12032-014-0311-2CrossRefPubMed

15.

Cannon NA, Meyer J, Iyengar P, Ahn C, Westover KD, Choy H, Timmerman R (2015) Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. J Thorac Oncol 10(2):280–285. https://doi.org/10.1097/JTO.0000000000000399CrossRefPubMed

16.

Templeton AJ, Ace O, McNamara MG et al (2014) Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev 23(7):1204–1212. https://doi.org/10.1158/1055-9965.EPI-14-0146CrossRef

17.

Zhou X, Du Y, Huang Z et al (2014) Prognostic value of PLR in various cancers: a meta-analysis. PLoS One 9(6):e101119. https://doi.org/10.1371/journal.pone.0101119CrossRefPubMedPubMedCentral

18.

Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Satomi T (2002) Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 9(3):287–291. https://doi.org/10.1007/BF02573067CrossRefPubMed

19.

Nie D, Yang E, Li Z (2019) Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis. BMC Cancer 19(1):73. https://doi.org/10.1186/s12885-018-5264-yCrossRefPubMedPubMedCentral

20.

Reagan MR, Ghobrial IM (2012) Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin cancer Res an Off J Am Assoc Cancer Res 18(2):342–349. https://doi.org/10.1158/1078-0432.CCR-11-2212CrossRef

21.

Kelkitli E, Atay H, Cilingir F et al (2014) Predicting survival for multiple myeloma patients using baseline neutrophil/lymphocyte ratio. Ann Hematol 93(5):841–846. https://doi.org/10.1007/s00277-013-1978-8CrossRefPubMed

22.

Onec B, Okutan H, Albayrak M et al (2017) The predictive role of the neutrophil/lymphocyte ratio in survival with multiple myeloma: a single center experience. J Clin Lab Anal 31(2). https://doi.org/10.1002/jcla.22032

23.

Romano A, Parrinello NL, Consoli ML, Marchionni L, Forte S, Conticello C, Pompa A, Corso A, Milone G, di Raimondo F, Borrello I (2015) Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. Ann Hematol 94(11):1875–1883. https://doi.org/10.1007/s00277-015-2462-4CrossRefPubMedPubMedCentral

24.

Mu S, Ai L, Fan F, Sun C, Hu Y (2018) Prognostic role of neutrophil-lymphocyte ratio in multiple myeloma: a dose-response meta-analysis. Onco Targets Ther 11:499–507. https://doi.org/10.2147/OTT.S153146CrossRefPubMedPubMedCentral

25.

Zeng Q, Liu Z, Li Q, Liu T (2018) Prognostic value of neutrophil to lymphocyte ratio and clinicopathological characteristics for multiple myeloma: a meta-analysis. Medicine (Baltimore) 97(41):e12678. https://doi.org/10.1097/MD.0000000000012678CrossRef

26.

Li Y, Li H, Li W et al (2017) Pretreatment neutrophil/lymphocyte ratio but not platelet/lymphocyte ratio has a prognostic impact in multiple myeloma. J Clin Lab Anal 31(5). https://doi.org/10.1002/jcla.22107

27.

Shi L, Qin X, Wang H et al (2017) Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma. Oncotarget 8(12):18792–18801. https://doi.org/10.18632/oncotarget.13320CrossRefPubMed

28.

Solmaz S, Uzun O, Acar C, Sevindik OG, Piskin O, Ozsan HG, Demirkan F, Undar B, Alacacioglu A, Ozcan MA, Alacacioglu I (2018) Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma? J Lab Physicians 10(4):363–369. https://doi.org/10.4103/JLP.JLP_36_18CrossRefPubMedPubMedCentral

Title: Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen
Authors: Aneta Szudy-Szczyrek
Radosław Mlak
Michał Mielnik
Michał Szczyrek
Aleksandra Nowaczyńska
Iwona Homa-Mlak
Szymon Zmorzyński
Kinga Kuśmierczuk
Jacek Sompor
Agata Filip
Teresa Małecka-Massalska
Marek Hus
Publication date: 01-12-2020
Publisher: Springer Berlin Heidelberg
Keyword: Multiple Myeloma
Published in: Annals of Hematology / Issue 12/2020
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-04092-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2020

Bone marrow coexistence of chronic lymphocytic leukemia and Langerhans cell sarcoma

Effect of allogeneic HCT from unrelated donors in AML patients with intermediate- or poor-risk cytogenetics: a retrospective study from the Japanese Society for HCT

Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status

Alloimmunization and autoimmunization in adult transfusion-dependent thalassemia patients: a report from a comprehensive center in Israel

Unique evolution of angioimmunoblastic T cell lymphoma to Epstein-Barr virus–positive plasma cell myeloma

Validation and comparison of prognostic values of GNRI, PNI, and CONUT in newly diagnosed diffuse large B cell lymphoma

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page